secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)
CIK:        0001742927
Form:       8-K
Filed at:   2023-10-30T23:59:59+00:00
Accession:  0001437749-23-029310
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Reviva announces positive Phase 3 RECOVER trial results for brilaroxazine in schizophrenia
--------------------------------------------------------------------------------

- Primary endpoint met: brilaroxazine 50 mg showed 10.1-point PANSS reduction vs placebo (p<0.001) at week 4.
- Statistically significant improvements in all major symptom domains and secondary endpoints at 50 mg dose.
- Well-tolerated with no drug-related SAEs; discontinuation rates lower than placebo (16% vs 22%).
- Plans to report OLE topline data in Q4 2024 and initiate Phase 3 RECOVER-2 in Q1 2024; NDA submission expected 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1742927/000143774923029310/0001437749-23-029310-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1742927/000143774923029310/rvph20231029_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-029310

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer